Ethyl pyruvate (EP)-based therapy for TIIDM and obesity-associated metabolic deficits: Ethyl pyruvate (EP) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 20/March/2018, 12.31 pm